September 03, 2025

FDA Approves Denosumab Biosimilars

The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.

Conexiant

September 03, 2025

Policy Shift Adjusts NIH Peer Review Role

New NIH funding rules shift decision-making power from peer review panels to political appointees in determining future scientific grants.

KFF Health News

September 02, 2025

New Bruton’s Tyrosine Kinase Inhibitor Improves Platelet Response

The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.

Conexiant

August 28, 2025

CD68/CD163 Mark Worse Outcomes in Skeletal Hodgkin Lymphoma, Study

Skeletal classic Hodgkin lymphoma shows a macrophage-rich, B-cell–poor microenvironment, with high CD68/CD163 linked to worse survival.

Conexiant

August 19, 2025

‘Enough Is Enough’—But When?

How Bogalusa, Louisiana became a lens on the US gun violence epidemic—where race, poverty, policy, and profit converge and communities bear the cost.

KFF Health News

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

February 12, 2025

FDA & EMA: Submitted Trial Data Discrepancies

Sample size discrepancies were identified in 13 trials (65%), with 8 differing by more than 10%.

Conexiant

March 21, 2025

Vutrisiran Receives FDA Nod for ATTR Amyloidosis With Cardiomyopathy

The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Conexiant

March 10, 2025

AI Methods Strengthen Real-World Data Reliability

Researchers assessed the impact of AI-driven methods on real-world data reliability, showing improvements in accuracy, completeness, and traceability

Conexiant